Amplify Treatments, Testing and Advancements ETF
GERM
GERM was delisted on the 5th of September, 2024.
0 hedge funds and large institutions have $0 invested in Amplify Treatments, Testing and Advancements ETF in 2024 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $3.83K → $0 (-$3.83K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IA
IFP Advisors
Tampa,
Florida
|
-$3.83K |
GERM Hedge Fund Activity: Q4 2024 in Review
0 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Amplify Treatments, Testing and Advancements ETF (GERM) for Q4 2024, worth a combined $0 — down 100% from $3.83K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of GERM and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was IFP Advisors, exiting entirely with an estimated $3.83K sold.
- 0 institutional investors held Amplify Treatments, Testing and Advancements ETF (GERM) as of Q4 2024, down from 1 in Q3 2024.
- Funds reported $0 of Amplify Treatments, Testing and Advancements ETF stock for Q4 2024, down 100% quarter-over-quarter.
- 0 funds opened new Amplify Treatments, Testing and Advancements ETF positions in Q4 2024 and 1 closed out, a net change of -1 holder.
- The largest Amplify Treatments, Testing and Advancements ETF seller in Q4 2024 was IFP Advisors, an estimated $3.83K sold.
Based on aggregated 13F filings for Q4 2024.